GlassScriptPhysician profile
Amanda M King
NPI 1922405687
$2,885.39
in general payments reported to CMS, 2019-2025
31 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $1,144 · 2023: $1,089 · 2024: $271 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $589.10 | 2021-2023 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $495.18 | 2022-2023 | |
| Lilly USA, LLC | $271.85 | 2021-2024 | Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $234.77 | 2022-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $130.92 | 2022-2023 | |
| Glaxosmithkline, LLC. | $124.90 | 2021-2024 | Trelegy Ellipta |
| Inspire Medical Systems, INC. | $120.58 | 2023 | Inspire |
| Amgen INC. | $105.41 | 2022-2023 | Repatha, Otezla |
| W. L. Gore & Associates, INC. | $89.27 | 2024-2025 | Gore Tag Thoracic Branch Endoprosthesis, Gore Excluder Iliac Branch Endoprosthesis, Gore Tag Conformable Thoracic Endoprosthesis |
| Dexcom, INC. | $85.07 | 2021-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $69.54 | 2022-2023 | |
| Cvrx, INC. | $51.96 | 2024 | Barostim Neo System |
| Indivior INC. | $51.10 | 2021-2022 | |
| Stryker Corporation | $44.50 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Davol INC. | $42.94 | 2024 | Arista Ah Flexitip |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $38.99 | 2022 | |
| Biosense Webster, INC. | $35.70 | 2024 | Carto 3 |
| Horizon Therapeutics Plc | $34.65 | 2022 | |
| Idorsia Pharmaceuticals US INC | $29.38 | 2023 | Quviviq |
| Solventum Corporation | $28.41 | 2024 | Prevena |
| Insulet Corporation | $27.09 | 2023 | Omnipod |
| Averitas Pharma INC. | $24.54 | 2025 | Qutenza |
| E.R. Squibb & Sons, L.L.C. | $23.12 | 2023 | Camzyos |
| Sumitomo Pharma America, INC. | $22.63 | 2023 | Gemtesa |
| Philips North America LLC | $21.35 | 2024 | (Am5) Lead Management |
| Abbott Laboratories | $19.68 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.55 | 2022 | |
| Tolmar, INC. | $16.11 | 2023 | |
| Novartis Pharmaceuticals Corporation | $14.95 | 2022 | |
| Antares Pharma, INC. | $12.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.